옵션 체인은 다양한 행사가격과 만기일에 대한 ImmunityBio의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 ImmunityBio에 대한 시장 심리를 평가합니다..

ImmunityBio (NASDAQ:IBRX) 주식, 옵션 체인

IMMUNITYBIO INC

ImmunityBio

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

San,Jose,,California,Us,-,February,14,,2025:,Archer,Brand

Equities

Mid Cap

News

Movers

ACHR

DBRG

DGNX

IBRX

LUNR

OKLO

지난주 최고의 성과를 거둔 중형주는 다음과 같다. 풋락커, 아처 에비에이션, 디지털브릿지, 뉴스케일 파워, 디지넥스, 이뮤니티바이오, 오클로, 인튜이티브 머신스

풋락커·아처에비에이션 등 지난주 급등한 중형주 8종목 (5월 12~16일)

Quantum Computing

Trading Ideas

ALHC

BPMC

COMP

HEES

IONQ

MSFT

NVDA

OPCH

SEMR

1월 13일부터 17일까지 지난주에 최고의 실적을 거둔 중형주 8종목은 다음과 같다 .H&amp;E 이큅먼트 SEM러시 컴퍼스 블루프린트 얼라인먼트 옵션 케어 이뮤니티바이오 아이온큐

아이온큐, H&amp;E 이큅먼트, 이뮤니티바이오 등 지난주 급등한 중형주 (1월 13일~17일)

$BTC

IRTC

WULF

이들 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 이뮤니티바이오(NASDAQ:IBRX)의 주식은 회사가 재발성 B-세포 비호지킨 림프종에 대한 CAR-NK 세포 치료제의 1상 임상 연구에서 첫 환자에게 투여했다고 발표한 후 49.86% 상승했다.

트럼프 미디어와 스트라이드는 지난주 최고 성과를 보여준 10개 중형주 중 일부 (10월 21일-10월 25일)

ImmunityBio Inc

The leaders of the Group of Seven (G7) unveiled a new action plan for critical minerals on Tuesday, following their latest meeting in Kananaskis, Alberta. The initiative, designed to secure <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">global supplies of essential materials</a> for clean energy, defense, and digital technology, is a step toward building transparent, reliable supply chains and boosting investments in sustainable mineral production.
"We recognize the need to work together to increase investment in responsible critical minerals projects within the G7 and around the world," the leaders said in a <a target="_blank" href="https://www.pm.gc.ca/en/news/statements/2025/06/17/g7-critical-minerals-action-plan" rel="noreferrer noopener">joint statement</a> released at the end of the summit.
The document also highlighted the opportunity to establish mutually beneficial partnerships with developing countries, creating stable, long-term supply relationships that foster shared economic growth.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/politics/25/06/45992119/trump-cuts-g7-visit-short-calls-canada-deal-achievable" rel="noreferrer noopener">Trump Cuts G7 Visit Short, Calls Canada Deal ‘Achievable'</a>
While the action plan does not directly name China, it calls out "non-market policies and practices" that distort critical mineral supply chains. The semantics reflect a growing concern among G7 members over China's dominance in markets for rare earth elements and materials such as lithium, cobalt, and graphite—resources critical to electric vehicles, batteries, and military technology.
"Non-market policies and practices in the critical minerals sector threaten our ability to acquire many critical minerals," the statement said. "We will work together and with partners beyond the G7 to swiftly protect our economic and national security."
The plan outlines key areas of action, including the development of standards-based markets, increased public and private investment, and partnerships with mineral-rich countries. These efforts include streamlining permitting processes, mitigating investment risks, and promoting new mining, processing, and recycling technologies.
At a press conference, Canadian Prime Minister and G7 chair Mark Carney noted the urgency of securing reliable mineral supply chains.
"They [G7 leaders] acknowledged that both energy security and the digital transition are underpinned by secure and responsible critical mineral supply chains and that more collaboration is required, within and beyond the G7," Carney <a target="_blank" href="https://www.pm.gc.ca/en/news/statements/2025/06/17/g7-chairs-summary" rel="noreferrer noopener">said</a> in a summary. He also announced the creation of the Canada-led Critical Minerals Production Alliance to help guarantee supplies for advanced manufacturing and defense industries in partner nations.
G7 plans to address the matter further at the Conference on Critical Materials and Minerals, scheduled for September in Chicago.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45975943/these-3-gold-stocks-have-rocketed-50-thanks-to-a-floundering-dollar" target="_blank" rel="noreferrer noopener">These 3 Gold Stocks Have Rocketed 50%, Thanks To A Floundering Dollar</a></li>
</ul>
Photo via Shutterstock

Commodities

Politics

Events

Global

Markets

Market Vectors ETF Trust Market Vectors Gold Miners

iShares S&P GSSI Natural Resources Sector Index Fund

iShares Trust Dow Jones US Basic Materials Sector Index Fund

PICK

PowerShares Dynamic Basic Materials Sector Portfolio

Market Vectors Rare Earth/Strategic Metals Etf

REMX

RING

G7 Targets Supply Chain Security With Critical Minerals Plan

Jefferies analyst Roger Song downgrades Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) from Buy to Hold and lowers the price target from $28 to $11.

Downgrades

Price Target

Analyst Ratings

VERV

Jefferies Downgrades Verve Therapeutics to Hold, Lowers Price Target to $11

VMAR

Vision Marine's E-Motion 180E Approved Under California CORE, Unlocks Up To $170K Vouchers Per Vessel

Compass Point analyst Casey Alexander initiates coverage on Blue Owl Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTF#NYSE">OTF</a>) with a Buy rating and announces Price Target of $17.

Initiation

Compass Point Initiates Coverage On Blue Owl Technology with Buy Rating, Announces Price Target of $17

<ul>
<li>TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month1</li>
<li>Atogepant met the primary endpoint of fewer treatment discontinuations attributed to adverse events versus topiramate, and all six secondary endpoints achieved statistical significance for superiority versus topiramate, demonstrating clinical efficacy1</li>
<li>Full results from the TEMPLE study will be presented at an upcoming medical meeting</li>
</ul>

Biotech

Large Cap

Health Care

General

ABBV

AbbVie Announced Topline Results From Its Phase 3 TEMPLE Trial Of Atogepant Compared To The Highest Tolerated Dose Of Topiramate In Migraine Patients, The Study Met The Primary Endpoint

Small Cap Consumer Research analyst Eric Beder reiterates Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) with a Buy and maintains $4 price target.

Reiteration

VNCE

Small Cap Consumer Research Reiterates Buy on Vince Holding, Maintains $4 Price Target

Aurora Cannabis (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACB#TSX">ACB</a>) reported quarterly losses of $(0.35) per share. This is a 14.63 percent increase over losses of $(0.41) per share from the same period last year. The company reported $90.54 million in sales this quarter. This is a 34.31 percent increase over sales of $67.41 million the same period last year.

Earnings

TSX:ACB

Aurora Cannabis Q4 EPS $(0.35) Up From $(0.41) YoY, Sales $90.54M Up From $67.41M YoY

Needham analyst Quinn Bolton reiterates Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and maintains $85 price target.

MRVL

Needham Reiterates Buy on Marvell Tech, Maintains $85 Price Target

WIIM

SRRK

Scholar Rock shares are trading higher after a study showed its new drug combination preserves muscle during tirzepatide-induced weight loss.

STSS

Sharps Technology shares are trading higher after initiating the second shipment of its first commercial order of SoloGard syringes under a multi-year supply agreement with a US-based IV flushing solutions provider.

Rosenblatt analyst Catharine Trebnick maintains NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Buy and maintains $190 price target.

NICE

Rosenblatt Maintains Buy on NICE, Maintains $190 Price Target

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) with a Buy and maintains $18 price target.

ROIV

HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target

BDRX

Biodexa shares are trading higher after the company enrolled the first patient in its Phase 2a study of Tolimidone.

Vodafone Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOD#NASDAQ">VOD</a>) Vi (Vodafone Idea) and AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) announced a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45991304/vi-and-ast-spacemobile-announce-partnership-for-satellite-connectivity" rel="noreferrer noopener">strategic partnership on</a> Wednesday to expand mobile connectivity across India&#8217;s unconnected regions.
This collaboration will leverage AST SpaceMobile&#8217;s groundbreaking technology, which recently demonstrated successful voice and video calls from space using a standard mobile phone.
While India boasts over 1.1 billion mobile subscribers and extensive 4G and emerging 5G networks, satellite communication will prove crucial in expanding broadband cellular access to challenging terrains.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/space/25/04/45046112/ast-spacemobile-partners-with-us-science-foundation-to-protect-astronomy-observations-while-expanding-satellite-network" rel="noreferrer noopener">AST SpaceMobile Partners With US Science Foundation To Protect Astronomy Observations While Expanding Satellite Network</a>
This partnership will combine Vi&#8217;s national network with AST SpaceMobile&#8217;s revolutionary space-based cellular technology. This technology connects directly to smartphones without specialized software, device support, or updates.
Aligned with Digital India&#8217;s initiatives, AST SpaceMobile and Vodafone Idea will collaborate on the SpaceMobile Satellite System.
The space-based cellular broadband ecosystem will be designed to expand Vi&#8217;s terrestrial connectivity telecom services, providing voice, video, data streaming, and internet access.
It will encompass the design, implementation, and launch of this system, wherein AST SpaceMobile will develop, manufacture, and manage the satellite constellation, and Vi will oversee terrestrial network integration, operating spectrum, and market access.
This announcement comes on the heels of other significant developments in India&#8217;s satellite internet landscape, including Elon Musk&#8217;s SpaceX <a target="_blank" href="https://www.benzinga.com/general/space/25/03/44244377/elon-musks-spacex-partners-with-airtel-to-launch-starlink-in-india-weeks-after-pm-narendra-modis-us-visit" rel="noreferrer noopener">partnering with Indian telecom company</a> Bharti Airtel in March to offer Starlink satellite internet services.
India&#8217;s Department of Telecommunications had requested&nbsp;security assurances&nbsp;from satellite communication providers like Starlink and Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).
Starlink and Amazon&#8217;s Project Kuiper&nbsp;have also advocated for reduced spectrum charges and long-term licenses to make satellite services more affordable for Indian consumers.
ASTS&nbsp;Price Action: ASTS stock is trading higher by 3.39% to $41.46 premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/24/12/42536024/taiwan-eyes-amazons-kuiper-as-starlink-faces-hurdles" target="_blank" rel="noreferrer noopener">Amazon&#8217;s Project Kuiper In Talks With Taiwan For Satellite Partnership</a></li>
</ul>
Photo via Shutterstock

Asia

Tech

AMZN

ASTS

Vodafone, AST SpaceMobile Partner To Bring Satellite Phone Service To Remote Parts Of India

LITM

Snow Lake Completes 2,719 Meters Of RC Drilling At Engo Valley With 8 Of 31 Holes Returning Significant Uranium Mineralization

Rosenblatt analyst Kevin Cassidy maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and maintains $124 price target.

Rosenblatt Maintains Buy on Marvell Tech, Maintains $124 Price Target

AXSM

Axsome Says It Will Present SYMBRAVO Migraine Treatment Data From Multiple Trials At AHS 2025 Annual Meeting

President Donald Trump met with Canadian Prime Minister Mark Carney on the sidelines of the G7 summit in Kananaskis, Alberta, on Monday. The media anticipated the conversation to clarify the tense U.S.-Canada relations, which have been strained over tariff escalations and a repeated proposal to <a target="_blank" href="https://www.benzinga.com/25/02/43582659/trump-says-canada-much-better-off-being-the-51st-state-the-border-with-us-is-just-a-line" rel="noreferrer noopener">annex the country as the 51st state</a>.
However, Carney's election in April promised to rebuild a more equal partnership between Ottawa and Washington, shifting the narrative to one of a more pragmatic nature.
"I'm a tariff person," Trump said in a <a target="_blank" href="https://www.youtube.com/watch?v=azGiHYbeiTU" rel="noreferrer noopener">video</a> posted by the Associated Press, explaining his stance on trade.&nbsp;"It's simple, it's easy, it's precise," he added, noting that Carney had "a different concept" but that they would explore both approaches.
Despite their differing philosophies, Trump confirmed a deal was "achievable" within weeks, hinting at openness to negotiation.
Josh Lipsky of the Atlantic Council's GeoEconomics Center reflected on the cautiously optimistic meeting.
"Is it tense? Yes. Is it awkward? Yes. The vibe would be best described as, ‘Let's just get through this.' Everyone is there, and everyone doesn't want a major dust-up," he said <a target="_blank" href="https://www.nytimes.com/2025/06/16/world/canada/canada-g7-trump-carney.html" rel="noreferrer noopener">per</a> the NY Times.
Journalists pressed Trump on key issues, including what was preventing a trade deal. Trump noted active talks between the two parties before turning to criticize former President Barack Obama and former Canadian Prime Minister Justin Trudeau for their role in removing Russia from (what was once) the G8.
"That was a big mistake," Trump said. "You wouldn't have a war right now if Russia had been at the table. If I were president four years ago, you wouldn't have this war."
He also responded to a question about China's inclusion in the G7, calling it "not a bad idea," but clarified that one needs partners with whom they can discuss matters.
The biggest elephant in the room was probably the ongoing conflict between Israel and Iran. When asked about potential U.S. military involvement, he refused to comment.
However, he noted that there was further action to be taken. "They (Iran) want to make a deal …And as soon as I leave here, we're going to be doing something. But I have to leave here," suggesting imminent developments.
Trump and Carney agreed to pursue further negotiations and a potential deal over the next 30 days before Trump cut the visit short and returned to Washington.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/06/45972264/senate-advances-stablecoin-bill-a-defining-moment-for-crypto-market-regulation" target="_blank" rel="noreferrer noopener">Senate Advances Stablecoin Bill: A Defining Moment For Crypto Market Regulation</a></li>
</ul>
Photo courtesy: Shutterstock

Media

BBCA

FLCA

ITOT

Trump Cuts G7 Visit Short, Calls Canada Deal 'Achievable'

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Western Copper &amp; Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WRN#AMEX">WRN</a>) with a Buy and lowers the price target from $4.25 to $4.

HC Wainwright & Co. Maintains Buy on Western Copper & Gold, Lowers Price Target to $4

New offering delivers convenient, comprehensive lab testing solutions for functional medicine, integrative medicine and primary care providers
BURLINGTON, N.C., June 18, 2025 /PRNewswire/ -- Labcorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), a global leader of innovative and comprehensive laboratory services, announced today the launch of <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4451797-1&amp;h=670611564&amp;u=https%3A%2F%2Fwww.labcorp.com%2Fproviders%2Fwhole-health-solutions&amp;a=Labcorp+Whole+Health+Solutions">Labcorp Whole Health Solutions</a>&nbsp;to support the growing needs of functional medicine, integrative medicine and primary care providers in delivering holistic care. The solution launches specialized test panels and a tailored test menu of more than 1,000 scientifically backed biomarkers for cardiometabolic health, hormones, micronutrients, longevity and whole body wellness.

Laboratory Corporation Of America Holdings

Labcorp Launches Labcorp Whole Health Solutions To Expand Holistic Care Offerings

Press Releases

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

Opinion

As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry

Comments

ImmunityBio

ImmunityBio (IBRX) 옵션

ImmunityBio (NASDAQ:IBRX) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌